Merck’s Keytruda (pembrolizumab), a cornerstone of modern oncology, maintained its position as the pharmaceutical industry’s leading brand in Fiscal Year…
Read More

Merck’s Keytruda (pembrolizumab), a cornerstone of modern oncology, maintained its position as the pharmaceutical industry’s leading brand in Fiscal Year…
Read More
The European Commission (EC) has granted approval for Keytruda (pembrolizumab) in combination with paclitaxel, with or without bevacizumab, as a…
Read More
In a significant development poised to reshape the competitive landscape of cancer therapeutics, global pharmaceutical giant MSD (known as Merck…
Read More